Skip to main content

Risk Management of the Minimum CMC Regulatory Compliance Continuum

  • Chapter
  • First Online:
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

Abstract

The challenge of control of the biopharmaceutical manufacturing process coupled with the complexity of the resulting biopharmaceutical products create pressure on meeting the CMC regulatory compliance requirements expected by regulatory authorities. Fortunately, the regulatory authorities accept a strategy that embraces a ‘minimum CMC regulatory compliance continuum’ for biopharmaceuticals (both protein-based and gene therapy-based). In this chapter, it will be discussed how the minimum CMC regulatory compliance continuum can be achieved by applying a strategic risk-based approach toward three interactive components – (1) CMC Regulatory, (2) cGMPs, and (3) the Quality System. A strategic risk-based approach recommended by the regulatory authorities – Quality by Design/Quality Risk Management (QbD/QRM) – will also be examined in detail.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. ICH website: Members and Observers; www.ich.org/page/members-observers

  2. ICH website: Consideration Documents – Gene Therapy Discussion Group; www.ich.org/page/consideration-documents

  3. FDA CFR Code of Federal Regulations Title 21 – Part 312.23, IND Content and Format; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.23

  4. EMA Guideline on Quality, Non-Clinical and Clinical Requirements for Investigational Advanced Therapy Medicinal Products in Clinical Trials (January 2019); www.ema.europa.eu/en/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal

  5. FDA Guidance for Industry: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) (January 2020); www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug

  6. EMA Guideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials (January 2022); www.ema.europa.eu/en/requirements-quality-documentation-concerning-biological-investigational-medicinal-products-clinical

  7. FDA Guidance for Industry: Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products (March 2022); www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-development-chimeric-antigen-receptor-car-t-cell-products

  8. FDA Guidance for Industry: CGMP for Phase 1 Investigational Drugs (July 2008); www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-phase-1-investigational-drugs

  9. European Commission EudraLex – Volume 4 – Good Manufacturing Practice (GMP) Guidelines – Guidelines on Good Manufacturing Practice Specific for Advanced Therapy Medicinal Products (November 2017); health.ec.europa.eu/system/files/2017-11/2017_11_22_guidelines_gmp_for_atmps_0.pdf

  10. ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (November 2000); /database.ich.org/sites/default/files/Q7%20Guideline.pdf

  11. FDA website: Facts About Current Good Manufacturing Practices (CGMPs); www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps

  12. PDA Technical Report 56: Application of Phase-Appropriate Quality System and cGMP to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance) (November 2016); www.pda.org/bookstore/product-detail/3474-tr-56-rev-application-of-phase-appropriate-quality

  13. ICH Q10: Pharmaceutical Quality System (June 2008); database.ich.org/sites/default/files/Q10%20Guideline.pdf

  14. International Pharmaceutical Quality (IPQ), Genzyme Viral Contamination Lessons Implemented in New Biotech Plant; Virus Control Draws Agency/Industry Dialogue (February 8, 2012); https://subscriber.ipq.org/genzyme-viral-contamination-lessons-implemented-in-new-biotech-plant-virus-control-draws-agencyindustry-dialogue/

  15. U.S. House Committee on Oversight and Reform: Committees’ Report on Emergent BioSolutions Uncovers Extensive Vaccine Manufacturing Failures, Deliberate Efforts to Hide Deficiencies (May 2022); oversight.house.gov/news/press-releases/committees-report-on-emergent-biosolutions-uncovers-extensive-vaccine

  16. ICH Q8(R2): Pharmaceutical Development (August 2009); database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf

  17. ICH Q9: Quality Risk Management (November 2005); database.ich.org/sites/default/files/Q9%20Guideline.pdf

  18. Rathore AS, Mhatre R. Quality by design for biopharmaceuticals: principles and case studies. New Jersey: Wiley; 2009.

    Book  Google Scholar 

  19. Kelley B. Quality by design for monoclonal antibodies – description of an integrated system. Biologicals. 2016;44(5):281. www.sciencedirect.com/journal/biologicals/vol/44/issue/5

    Article  PubMed  Google Scholar 

  20. PDA Technical Reports; store.pda.org/TableOfContents/PDA_Technical_Reports_list.pdf

  21. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL): N-mAb – A Case Study to Support Development and Adoption of Integrated Continuous Bioprocesses for Monoclonal Antibodies (June 2022); www.niimbl.org/Downloads/N-mAb/N-mAb_Version1.pdf

  22. Alliance for Regenerative Medicine: Project A-Gene – A Case Study-Based Approach to Integrating QbD Principles in Gene Therapy CMC Programs (2021); alliancerm.org/manufacturing/a-gene-2021

  23. EMA Medicines – European Public Assessment Report: Phesgo (Pertuzumab/Trastuzumab) EPAR (January 2021); www.ema.europa.eu/en/medicines/human/EPAR/phesgo

  24. ICH Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) (May 2012); database.ich.org/sites/default/files/Q11%20Guideline.pdf

  25. CMC Biotech Working Group: A-mAb – A Case Study in Bioprocess Development (October 2009); ispe.org/sites/default/files/initiatives/pqli/a-mab-case-study-version.pdf

  26. EMA Medicines – European Public Assessment Report: Gazyvaro (Obinutuzumab) EPAR (May 2014); www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro

  27. Lamerz J, Danila OM, et al. An improved impact ratio for identifying critical process parameters in pharmaceutical manufacturing processes. PDA J Pharm Sci Technol. 2022;76(6):497–508.

    Article  PubMed  Google Scholar 

  28. FDA Drug Databases: Drugs@FDA – FDA Approved Drug Products – Vabysmo (Faricimab-svoa) – Administrative and Correspondence Documents – Pre-BLA Meeting Minutes (March 29, 2021); www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761235Orig1s000AdminCorres.pdf

  29. FDA Drug Databases: Drugs@FDA – FDA Approved Drug Products – Tecvayli (Teclistamab-cqyv) – Administrative and Correspondence Documents – Pre-BLA Meeting Minutes (May 26, 2021); www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761291Orig1s000AdminCorres.pdf

  30. EMA Medicines – European Public Assessment Report: Polivy (Polatuzumab Vedotin) EPAR (January 2020); www.ema.europa.eu/en/medicines/human/EPAR/polivy

  31. FDA Drug Databases: Drugs@FDA – FDA Approved Drug Products – Gazyva (Obinutuzumab) Market Approval Letter (November 2013); www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/125486Orig1s000ltr.pdf

  32. ICH Q9(R1) Draft: Quality Risk Management (November 2021); database.ich.org/sites/default/files/ICH_Q9-R1_Document_Step2_Guideline_2021_1118.pdf

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Geigert, J. (2023). Risk Management of the Minimum CMC Regulatory Compliance Continuum. In: The Challenge of CMC Regulatory Compliance for Biopharmaceuticals. Springer, Cham. https://doi.org/10.1007/978-3-031-31909-9_4

Download citation

Publish with us

Policies and ethics